Kedrion and ProMetic Form Strategic Alliance to Develop Orphan Drugs from Plasma
15-Mar-2007 -
Kedrion S.p.A. and ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. have formed a strategic alliance to develop orphan drugs derived from human plasma utilizing ProMetic's proprietary manufacturing process, the Plasma Protein Purification System (PPPS).
The alliance ...
diseases
Orphan Drug Designation
Orphan Drug Status
+6